Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a compound pharmaceutical composition in preparation of medicine for treating acute kidney injury

A composition and drug technology, applied in the directions of drug combinations, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as acute kidney injury without serotonin 2 receptor antagonists, and achieve obvious synergistic effects and significant effects.

Active Publication Date: 2022-03-08
CHINA PHARM UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] At present, there is no report on the use of serotonin 2 receptor antagonist sarcogrelate and / or serotonin synthesis inhibitor for the treatment of acute kidney injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a compound pharmaceutical composition in preparation of medicine for treating acute kidney injury
  • Application of a compound pharmaceutical composition in preparation of medicine for treating acute kidney injury
  • Application of a compound pharmaceutical composition in preparation of medicine for treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Changes of renal 5-HT synthase, 5-HT2A receptor and MAO-A expression in cisplatin-induced acute kidney injury in mice

[0032] 1.1 Experimental method

[0033] Male ICR mice, weighing 20-28g, were used in the experiment. Animal cages were kept in common mouse cages, room temperature was kept at 24±2°C, light was controlled to ensure light and dark conditions for 12 hours, and normal water was fed. Animal models of acute kidney injury (AKI) were established by intraperitoneal injection (i.p.) of cisplatin (Cisplatin, 25 mg / kg), and the control group was i.p. equal volume of normal saline. Animals were sacrificed 72 hours after cisplatin injection, and blood and kidneys were collected to detect relevant indicators.

[0034] Protein was extracted from the homogenized kidney tissue, and Western blot was used to detect 5-HT synthase Tph1, AADC, and 5-HT2A receptor (5-HT 2A R) and protein expression of the 5-HT degrading enzyme monoamine oxidase A (MAO-A). After cisplatin-...

Embodiment 2

[0038] Therapeutic Effects of Drugs on Acute Kidney Injury Induced by Cisplatin in Mice

[0039] To compare the therapeutic effect of sargrelate (Sar) in combination with carbidopa (CDP) or benserazide (BSA), and each individual administration on cisplatin-induced acute kidney injury (AKI) in mice, so as to verify the effect of Sar Synergistic effect of coadministration with CDP or BSA on the treatment of AKI.

[0040] 2.1 Experimental method

[0041] (1) Animal handling

[0042] The male ICR mice used in the experiment, weighing 18-28g, were housed in ordinary mouse cages, kept at room temperature of 24±2°C, light controlled to ensure light and dark conditions for 12 hours, and fed with ordinary water.

[0043] The experiment was done in two batches. The first batch of animals were randomly divided into 8 groups (12 animals in each group): control group, cisplatin (Cisplatin) induced AKI model group, AKI model Sar treatment group, AKI model Sar+CDP compound treatment group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a compound pharmaceutical composition in the preparation of medicines for treating acute kidney injury. The compound pharmaceutical composition in the invention uses sarcogrelate and a 5-serotonin synthesis inhibitor as active ingredients, and the 5-serotonin synthesis inhibitor Carbidopa or benserazide. Sagrelate and carbidopa or benserazide can inhibit the synthesis of 5-HT 2 receptors and 5-HT in kidney cells, and have an obvious synergistic effect on the treatment of acute kidney injury, and have a significant effect on the treatment of acute kidney injury. Effect.

Description

technical field [0001] The invention relates to the application of the pharmaceutical composition, in particular to the application of a compound pharmaceutical composition in the preparation of medicines for treating acute kidney injury. Background technique [0002] Acute kidney injury (AKI) is a group of clinical syndromes, which refers to sudden (within 1-7d) and sustained (>24h) sudden decline in renal function, defined as an increase in serum creatinine (CRE) of at least 0.5mg / dl, manifested as azotemia, water-electrolyte and acid-base balance, and systemic symptoms of the whole body, which may be accompanied by oliguria (<400ml / 24h or 17ml / h) or anuria (<100ml / 24h). AKI is a common clinical emergency and severe renal disease, and the incidence of AKI is still high. Chronic kidney disease (CKD) caused by AKI and its further development is still a major problem in China's and even the world's medical and health services, mainly because there is no very effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/225A61K31/198A61K31/165A61P13/12
CPCA61K45/06A61K31/225A61K31/198A61K31/165A61P13/12A61K2300/00
Inventor 傅继华
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com